JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266031

Human UBE2K (HIP2/LIG) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

UBE2K KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Western blot - Human UBE2K (HIP2/LIG) knockout HeLa cell line (AB266031)
  • WB

Lab

Western blot - Human UBE2K (HIP2/LIG) knockout HeLa cell line (AB266031)

Lanes 1-4 : Merged signal (red and green). Green - ab52930 observed at 26 kDa. Red - loading control ab8245 observed at 36 kDa.

ab52930 Anti-HIP2/LIG antibody [EP1145Y] was shown to specifically react with HIP2/LIG in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab266031 (knockout cell lysate ab257778) was used. Wild-type and HIP2/LIG knockout samples were subjected to SDS-PAGE. ab52930 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-HIP2/LIG antibody [EP1145Y] (<a href='/en-us/products/primary-antibodies/hip2-lig-antibody-ep1145y-ab52930'>ab52930</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

UBE2K knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human UBE2K (HIP2/LIG) knockout HeLa cell line (ab266031)

Lane 3:

Jurkat cell lysate at 20 µg

Lane 4:

Daudi cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 22 kDa

Observed band size: 26 kDa

false

Sanger Sequencing - Human UBE2K (HIP2/LIG) knockout HeLa cell line (AB266031)
  • Sanger seq

Unknown

Sanger Sequencing - Human UBE2K (HIP2/LIG) knockout HeLa cell line (AB266031)

Homozygous : 1 bp deletion in exon1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266031-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB266031-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266031 Human UBE2K (HIP2/LIG) knockout HeLa cell line", "number":"AB266031-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266031-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266031 Human UBE2K (HIP2/LIG) knockout HeLa cell line", "number":"AB266031-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB266031-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266031-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266031 Human UBE2K (HIP2/LIG) knockout HeLa cell line", "number":"AB266031-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266031-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266031 Human UBE2K (HIP2/LIG) knockout HeLa cell line", "number":"AB266031-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
UBE2K
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

HIP2 also known as LIG or Ubiquitin-Conjugating Enzyme E2 K (UBE2K) functions as an E2 ubiquitin-conjugating enzyme. It has a molecular mass of approximately 24 kDa. This protein plays an important role in the ubiquitination process where it transfers ubiquitin molecules to substrate proteins labeling them for degradation. HIP2 is expressed across various tissues in the human body indicating its widespread importance in cellular activities. It works alongside ubiquitin ligases (E3s) to ensure accurate tagging of proteins facilitating their removal by the proteasome.
Biological function summary

The function of HIP2 extends to protein homeostasis essential for maintaining cellular integrity. As part of the ubiquitin-proteasome system it ensures the elimination of damaged or excess proteins effectively preventing cellular stress or dysfunction. HIP2 operates within a complex that includes E1 enzymes and various E3 ligases highlighting its collaborative nature in protein turnover. The protein activity helps regulate cell cycle progression DNA repair and signal transduction ensuring normal cell function and adaptation to environmental changes.

Pathways

HIP2 is most involved in the ubiquitin-proteasome pathway and is linked to protein catabolism. It collaborates with key proteins like UBE2C and UBE2D which participate in tagging proteins for degradation. The coordination with these proteins demonstrates HIP2's role in managing protein levels in cells having implications in the cell's response to damage and stress. Additionally HIP2 intersects with pathways associated with cell cycle regulation allowing cells to maintain orderly division and prevent the accumulation of aberrant proteins.

HIP2 is significantly associated with neurodegenerative conditions and cancers. Aberrant HIP2 function can affect pathways controlled by proteins like p53 resulting in insufficient protein degradation that contributes to neuronal accumulation in disorders such as Alzheimer's disease. Moreover HIP2 dysregulation has links to oncogenic processes connecting to proteins like cyclins which are critical regulators in various cancers. Investigation into HIP2's function offers insights into potential therapeutic targets for these severe conditions with ongoing research focusing on modulating its activity to manage or prevent disease progression.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com